Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 PosttranslationalModification disease BEFREE In P210 (+) chronic myelogenous leukemia (CML), down-regulated PAK1 gene expressions may lead to the suppression of cell proliferation and promotion of apoptosis through phosphorylation of STAT5, with a reverse effect in P190 (+) acute lymphoblastic leukemia(ALL), especially acute B lymphoblastic leukemia (B-ALL). 30784762 2019
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE The breakpoint cluster region-ABL proto-oncogene 1 (<i>BCR-ABL</i>) rearrangement leads to a p210 chimeric protein in typical chronic myeloid leukemia (CML), whereas 17-25% of patients with acute lymphocytic leukemia and 0.9-3% patients with <i>de novo</i> acute myeloid leukemia (AML) carry a p190<sup>BCR-ABL</sup> fusion protein. 29151902 2017
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Two models of leukemia were used, one genetic (conditional alpha4 ablation of BCR-ABL1 [p210(+)] leukemia) and one pharmacological (anti-functional alpha4 antibody treatment of primary ALL). 23319569 2013
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Here we investigated whether there are differences between p185(BCR/ABL) and p210(BCR/ABL) regarding their sensitivity towards allosteric inhibition by GNF-2 in models of Philadelphia chromosome-positive acute lymphatic leukemia. 22058195 2012
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 GeneticVariation disease BEFREE BCR-ABL breakpoints were identified in p190 ALL (n=25), p210 ALL (n=25) and p210 CML (n=32); reciprocal breakpoints were identified in 54 cases. 20703256 2010
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. 17717597 2007
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Treatment of Arf-/-, p210(Bcr-Abl)-positive pre-B cells with imatinib together with an inhibitor of JAK kinases abrogates this resistance, suggesting that this combination may prove beneficial in the treatment of BCR-ABL-positive acute lymphoblastic leukemia. 16618932 2006
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE We applied this assay to assess the distribution of p190 and p210 in 260 childhood ALL samples from India. 15681473 2005
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE In this study we adapted the multiplex RT-PCR assay, previously described by Pallisgaard et al., to detect all the most frequent genetic lesions with their characteristic splicing variants occurring in acute lymphoblastic leukemia, such as the MLL/AF4, MLL/ENL, BCR/ABL p190 (e1a2) and p210 (b2a2,b3a2) isoforms, E2A/PBX1, TEL/AML1, SIL/TAL1 and the novel NUP98/RAP1GDS1 transcript, recently described in a T-ALL leukemic subtype. 12651265 2003
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 GeneticVariation disease BEFREE An oligonucleotide microarray was designed for hybridization with products of a multiplex RT-PCR to identify the following translocations: t(9;22)p190, t(4;11), t(12;21), t(1;19), typical for acute lymphoblastic leukemia; t(9;22)p210 for chronic myeloid leukemia; and t(8;21), t(15;17), inv16, typical for acute myeloblastic leukemia. 14654544 2003
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 AlteredExpression disease BEFREE The most common form, p210 BCR-ABL1, is found in more than 90% of patients with chronic myelogenous leukaemia (CML) and in up to 15% of adult patients with de novoacute lymphoblastic leukaemia (ALL). 10615128 2000
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 GeneticVariation disease BEFREE The previously uncharacterized CDC24 homology domain of BCR, which is missing in the P185 BCR-ABL oncogene of Philadelphia chromosome (Ph1)-positive acute lymphocytic leukemia but is retained in P210 BCR-ABL of chronic myelogeneous leukemia, was found to bind to the xeroderma pigmentosum group B protein (XPB). 9874796 1999
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 AlteredExpression disease BEFREE We investigated this possibility by studying peripheral blood leukocytes from normal individuals and various hematopoietic cell lines for the presence and expression of the p210 and the p190 types of the BCR-ABL gene associated with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia. 9787174 1998
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Alternative chimeric proteins, p210(BCR-ABL) and p190(BCR-ABL), are produced that are characteristic of chronic myelogenous leukemia and acute lymphoblastic leukemia, respectively. 9096220 1997
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE The median ratio in p210 ALL was also low (1.9 x 10(-3)) but significantly higher than that of CML. 8652835 1996
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 AlteredExpression disease BEFREE This observation also confirmed that, as in de novo Ph1-positive ALL, both the P190 and P210 varieties of BCR-ABL mRNA are observed in ALL with late-appearing Ph1. 7564511 1995
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 GeneticVariation disease BEFREE Of the two P210 ALL patients, one had a Ib-b4 ABL-BCR transcript and the other showed no detectable ABL-BCR expression. 8490164 1993
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Finally, the relationship between the two common forms of BCR/ABL, the P190 and P210 configurations, and different disease phenotypes, like CML and Philadelphia (Ph1)-chromosome positive acute lymphoblastic leukemia (ALL), needs to be clarified. 8464245 1993
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Furthermore, the Mbcr-type breakpoint, associated with production of p210, can be seen in childhood leukemias presenting either as clinical ALL or as apparent lymphoid blast crisis of CML, suggesting that t(9;22) breakpoint locations do not exclusively determine the biologic and clinical features of pediatric Ph1-positive ALL. 1985699 1991
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE We investigated the significance of p210 and p190 molecular abnormalities in 32 adults with Philadelphia chromosome (Ph)-positive acute leukemia. p210 was detected in 15 patients (47%), p190 in 16 (50%), and both in one (3%). p210 was noted in 11 of 24 patients (46%) with acute lymphocytic leukemia, and in four of eight patients (50%) with acute myelogenous or undifferentiated leukemia. 1932753 1991
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 GeneticVariation disease BEFREE This results in an 8.7-kilobase mRNA that encodes the P210 BCR-ABL gene product commonly found in patients with chronic myelogenous leukemia or a 7.0-kilobase mRNA that produces the P185 BCR-ABL gene product found in most Philadelphia chromosome-positive patients with acute lymphocytic leukemia. 2747638 1989
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 Biomarker disease BEFREE Philadelphia chromosome positive acute lymphocytic leukemia and chronic myelogenous leukemia are strongly associated with two distinct forms of bcr-abl chimeric protein, known as P190 and P210, respectively. 2915904 1989
Entrez Id: 2125
Gene Symbol: EVPL
EVPL
0.100 GeneticVariation disease BEFREE A combination of monosomy 7 and translocation t(9;22) (q34;q11), rarely observed in acute lymphoblastic leukaemia (ALL), is here reported: a peculiarity of this case was that the "breakpoint cluster region" on chromosome 22 was not rearranged, as demonstrated by molecular analysis, and a new c-abl protein (p190) was found, instead of the usual p210 protein usually associated with the Ph chromosome; moreover a rearrangement of c-abl oncogene was found. 3480400 1987